Mallinckrodt
This article was originally published in The Gray Sheet
Executive Summary
FDA approves the Puritan-Bennett Achieva portable volume ventilator. Suitable for children and adults, Achieva's "enhanced performance and pressure support capabilities bring Mallinckrodt full force into the subacute market," the firm says. The device also features "extended battery life," internal memory and modem for accessing stored data. Separately, Mallinckrodt's Nellcor N-395 pulse oximeter with Oxismart XL advanced signal processing and SatSeconds alarm management technology gains additional 510(k) clearance for use with Nellcor Oxisensor II adhesive sensors. The device was originally cleared in August to read through motion and deliver accurate oxygen saturation and pulse rate values using Nellcor adult and neonatal sensors. The expanded clearance extends the motion claim to include Nellcor pediatric and infant sensors
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.